Signal from the log
R1 Therapeutics
77,5 M$ · Series A · United States · Biotech
Biotech américaine de néphrologie qui développe AP306, un médicament abaissant le phosphate sanguin chez les patients dialysés. Il bloque l'absorption active du phosphate au lieu de le capter après ingestion, ce qui doit réduire le nombre de comprimés à avaler chaque jour.
Verified
Announced on , logged by the watch of 17 August 2026.
- Operation
- Funding round
- Announced amount
- 77,5 M$
- Stage
- Series A
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by Abingworth , F-Prime , DaVita Venture Group , with Curie.Bio , SymBiosis , US Renal Care
Provenance
Source longevity
Logged on 17 August 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.